NIKKEI 225
38,079.70 0.00 (0.00%) HANG SENG
16,385.87 +134.03 (+0.82%) CRUDE OIL
82.62 -0.11 (-0.13%) GOLD FUTURES
2,395.20 -2.80 (-0.12%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
51,036.86 +1,846.21 (+3.75%)
AbbVie Inc. (ABBV)
After hours:
| Previous close | 164.25 |
| Open | 164.96 |
| Bid | 164.41 x 800 |
| Ask | 164.99 x 800 |
| Day's range | 164.43 - 167.44 |
| 52-week range | 130.96 - 182.89 |
| Volume | |
| Avg. volume | 5,659,933 |
| Market cap | 291.555B |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | 60.32 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 6.20 (3.77%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
- Benzinga
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson’s disease. The TEMPO-3 trial evaluated the efficacy, safety, and tolerability of tavapadon as an adjunctive therapy to levodopa (LD) in adults. The trial met its primary endpoint – patients treated with tavapadon adjunctive to LD experienced a clinically meaningful and statistically significant increase of 1.1 hours in total “on” time without tr
- Zacks
AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
AbbVie (ABBV) closed at $164.25 in the latest trading session, marking a +1.05% move from the prior day.
- Reuters
UPDATE 1-US FDA warns of harmful reactions to fake Botox injections
The U.S. Food and Drug Administration on Tuesday alerted health care professionals and consumers that unsafe counterfeit versions of AbbVie's Botox were given to consumers for cosmetic purposes in multiple states. The U.S. Centers for Disease Control and Prevention (CDC) and the FDA are investigating reports of harmful reactions among people who received injections of counterfeit Botox. As of April 12, a total of 19 people from nine states had reported harmful reactions after receiving Botox injections from unlicensed or untrained individuals, or in non-healthcare settings, such as homes and spas, according to the CDC.
